Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab and Radiation in Elderly/Poor PS NSCLC
NCT00124618Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jan 2006
- Primary completion
- Feb 2008
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in non-small cell lung cancer (NSCLC), sponsored by Cancer and Leukemia Group B. Primary endpoint: 11-month Survival Rate. Started Jan 2006; status: completed.
02
Drugs
cetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00124618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00124618.